Carbonic Anhydrase Inhibitors. Design of Selective, Membrane-Impermeant Inhibitors Targeting the Human Tumor-Associated Isozyme IX

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2337-2347

  Casey, Joseph R ^a   Morgan, Patricio E ^a   Vullo, Daniela ^b   Scozzafava, Andrea ^b   Mastrolorenzo, Antonio ^b   Supuran, Claudiu T ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 AMINOBENZENSULFONYLAMINO) 1,3,4 THIADIAZOLE 2 SULFONAMIDE; AMINOBENZOLAMIDE; BENZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; ISOENZYME; METALLOPROTEINASE; MULTIENZYME COMPLEX; PYRIDINIUM DERIVATIVE; SULFONAMIDE; TUMOR ASSOCIATED ISOZYME IX; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANION EXCHANGE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ASSAY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; ERYTHROCYTE MEMBRANE; HUMANS; ISOENZYMES; PERMEABILITY; PYRIDINIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 1842628633     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031079w     Document Type: Article

References (61)

1. Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J. P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E. J.; Zavada, J.; Burny, A.; Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase an a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2877-2888.
2. Pastorekova, S.; Parkkila, S.; Parkkila, A. K.; Opavsky, R.; Zelnik, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112, 398-408.
3. Chegwidden, W. R.; Spencer, I. M.; Supuran, C. T. The roles of carbonic anhydrase isozymes in cancer. In Gene Families: Studies of DNA, RNA, Enzymes and Proteins; Xue, G., Xue, Y., Xu, Z., Hammond, G. L., Lim, H. A., Eds.; World Scientific: Singapore, 2001; pp 157-169.
4. Teicher, B. A.; Liu, S. D.; Liu, J. T.; Holden, S. A.; Herman, T. S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 1993, 13, 1549-1556.
5. (a) Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Anticancer and antiviral sulfonamides. Curr. Med. Chem. 2003, 10, 925-953.
6. (b) Casini, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets 2002, 2, 55-75.
7. (a) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors. Curr. Med. Chem.-Imm., Endoc. Metab. Agents, 2001, 1, 61-97.
8. (b) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-189.
9. (a) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents 2000, 10, 575-600.
10. (b) Supuran, C. T.; Scozzafava, A. Applications of carbonic anhydrase inhibitors and activators in therapy. Exp. Opin. Ther. Patents 2002, 12, 217-242.
11. (a) Owa, T.; Nagasu, T. Novel sulphonamide derivatives for the treatment of cancer. Exp. Opin. Ther. Patents 2000, 10, 1725-1740.
12. (b) Owa T.; Yoshino H.; Okauchi T.; Yoshimatsu K.; Ozawa Y.; Sugi N. H.; Nagasu T.; Koyanagi N.; Kitoh K. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 1999, 42, 3789-3799.
13. (c) Supuran, C. T. Indisulam: An anticancer sulfonamide in clinical development. Exp. Opin. Investig. Drugs 2003, 12, 283-287.
14. (d) Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Indisulam (E7070) is a potent inhibitor of cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-223.
15. (a) Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703-714.
16. (b) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J. Enzyme Inhib. 2000, 15, 597-610.
17. (c) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors-Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents? Eur. J. Med. Chem. 2000, 35, 867-874.
18. (a) Scozzafava, A.; Briganti, F.; Ilies, M. A.; Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isozymes. J. Med. Chem. 2000, 43, 292-300.
19. (b) Supuran, C. T.; Scozzafava, A.; Ilies, M. A.; Iorga, B.; Cristea, T. ; Briganti, F.; Chiraleu, F.; Banciu, M. D. Carbonic anhydrase inhibitors. Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first nonpolymeric membrane-impermeable inhibitors with selectivity for isozyme IV. Eur. J. Med. Chem. 1998, 33, 577-594.
20. (c) Supuran, C. T.; Scozzafava, A.; Ilies, M. A.; Briganti, F. Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enzymol. Inhib. 2000, 15, 381-401.
21. Supuran, C. T.; Ilies, M. A.; Scozzafava, A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur. J. Med. Chem. 1998, 33, 739-752.
22. (a) Tinker, J. P.; Coulson, R.; Weiner, I. M. Dextran-bound inhibitors of carbonic anhydrase. J. Pharmacol. Exp. Ther. 1981, 218, 600-607.
23. (b) Maren, T. H.; Conroy; C. W.; Wynns, G. C.; Godman, D. R. Renal and cerebrospinal fluid formation pharmacology of a high molecular weight carbonic anhydrase inhibitor. J. Pharmacol. Exp. Ther. 1997, 280, 98-104.
24. (c) Heming, T. A.; Geers, C.; Gros, G.; Bidani, A.; Crandall, E. D. Effects of dextran-bound inhibitors on carbonic anhydrase activity in isolated rat lungs. J. Appl. Physiol. 1988, 61, 1849-1856.
25. (a) Sterling, D.; Brown, N. J. D.; Supuran, C. T.; Casey, J. R. The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am. J. Physiol.-Cell Physiol. 2002, 283, C1522-C1529.
26. (b) Alvarez, B.; Loiselle, F. B.; Supuran, C. T.; Schwartz, G. J.; Casey, J. R. Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry 2003, 42, 12321-12329.
27. (a) Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
28. (b) Ilies, M. A.; Vullo, D.; Pastorek, J.; Scozzafava, A.; Ilies, M.; Caproiu, M. T.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX with halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 2003, 46, 2187-2196.
29. (c) Winum, J.-Y.; Vullo, D.; Casini, A.; Montero, J.-L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II and the transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. 2903, 46, 2197-2204.
30. (a) Franchi, M.; Vullo, D.; Gallori, E.; Pastorek, J.; Russo, A.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J. Enzymol. Inhib. Med. Chem. 2003, 18, 333-338.
31. (b) Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J. Enzymol. Inhib. Med. Chem. 2003, 18, 403-406.
32. (a) Balaban, A. T.; Dinculescu, A.; Dorofeenko, G. N.; Fischer, G. W.; Koblik, A. V.; Mezheritskii, V. V.; Schroth, W. Pyrylium Salts: Syntheses, Reactions and Physical Properties. In Advances in Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1982; pp 8-360.
33. (b) Dinculescu, A.; Balaban, A. T. Reaction of pyrylium salts with nucleophiles. XIV. New pyridinium salts with potential biological activity. Rev. Roum. Chim. 1980, 25, 1505-1528.
34. (c) Toma, C.; Balaban, A. T. Reaction of pyrylium salts with nucleophiles. VI. Reaction with amino acids. Tetrahedron 1966, Suppl. 7, 27-34.
35. Pocker, Y.; Stone, J. T. The catalytic versatility of erythrocyte carbonic anhydrase. III. Kinetic studies of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate. Biochemistry 1967, 6, 668-678.
36. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. J. Biol. Chem. 1971, 246, 2561-2573.
37. (a) Supuran, C. T.; Clare, B. W. Carbonic anhydrase inhibitors Part 24. A quantitative structure-activity relationship study of positively charged sulfonamide inhibitors. Eur. J. Med. Chem. 1995, 30, 687-696.
38. (b) Clare, B. W.; Supuran, C. T. Carbonic anhydrase inhibitors Part 41. Quantitative structure-activity correlations involving kinetic rate constants of 20 sulfonamides from a noncongeneric series. Eur. J. Med. Chem. 1997, 32, 311-319.
39. (c) Supuran, C. T.; Clare, B. W. Carbonic anhydrase inhibitors Part 47. Quantum chemical quantitative structure-activity relationships for a group of sulfanilamide Schiff base inhibitors of carbonic anhydrase. Eur. J. Med. Chem. 1998, 33, 489-500.
40. (a) Ferraroni, M.; Briganti, F.; Chegwidden, W. R.; Supuran, C. T.; Wiebauer, K. E.; Tashian, R. E.; Scozzafava, A. Structures of the human carbonic anhydrase isoenzyme I Michigan 1 variant in the absence and in the presence of exogenous zinc(II) ions: A true and specific metal-ion activation. Biochemistry 2002, 41, 6237-6244.
41. (b) Ferraroni, M.; Briganti, F.; Chegwidden, W. R.; Supuran, C. T.; Scozzafava, A. Crystal analysis of aromatic sulfonamide binding to native and (Zn)2 adduct of human carbonic anhydrase I Michigan 1. Inorg. Chim. Acta 2002, 339, 135-144.
42. Gomaa, Z. S. Determination of acetazolamide in dosage forms by high performance liquid chromatography. Biomed. Chromatogr. 1993, 7, 134-135.
43. Abdine, H.; Elsayed, M. A.; Elsayed, Y. M. pH-Induced differenece spectrophotometric assay of acetazolamide, hydrochlorothiazide and furosemide. J. Assoc. Off. Anal. Chem. 1978, 61, 695-701.
44. Wistrand, P. J.; Lindqvist, A. Design of carbonic anhydrase inhibitors and the relationship between the pharmacodymanics and pharmacokinetics of acetazolamide. In Carbonic Anhydrase-From Biochemistry and Genetics to Physiology and Clinical Medicine; Botrè, F., Gros, G., Storey, B. T., Eds.; VCH: Weinheim, 1991; pp 352-378.
45. Maren T. H. Benzolamide - A renal carbonic anhydrase inhibitor. In Orphan Drugs; Karch, F. E., Ed.; M. Dekker: New York, 1982; pp 89-115.
46. Lindskog, S.; Behravan, G.; Engstrand, C.; Forsman, C.; Jonsson, B. H.; Liang, Z.; Ren, X.; Xue, Y. 1991. Structure-function relations in human carbonic anhydrase II as studied by site-directed mutagenesis. In Carbonic anhydrase - From biochemistry and genetics to physiology and clinical medicine; Botrè, F., Gros, G., Storey, B. T., Eds.; VCH: Weinheim, pp 1-13.
47. Behravan, G.; Jonsson, B. H.; Lindskog, S. Fine-tuning of the catalytic properties of carbonic anhydrase. Studies of a Thr200-His variant of human isoenzyme II. Eur. J. Biochem. 1990, 190, 351-357.
48. Khalifah, R. G.; Strader, D. J.; Bryant, S. H.; Gibson, S. M. Carbon-13 nuclear magnetic resonance probe of active site ionization of human carbonic anhydrase B. Biochemistry 1977, 16, 2241-2247.
49. Lindskog, S.; Coleman, J. E. The catalytic mechanism of carbonic anhydrase. Proc. Natl. Acad. Sci. U.S.A. 1964, 70, 2505-2508.
50. Steiner, H.; Jonsson, B. H.; Lindskog, S. The catalytic mechanism of carbonic anhydrase. Hydrogen-isotope effects on the kinetic parameters of the human C isoenzyme. Eur. J. Biochem. 1975, 59, 253-259.
51. Maren, T. H.; Wynns, G. C.; Wistrand, P. J. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme, Mol. Pharmacol. 1993, 44, 901-906.
52. Wingo, T.; Tu, C.; Laipis, P. J.; Silverman, D. N. The catalytic properties of human carbonic anhydrase IX. Biochem. Biophys. Res. Commun. 2001, 288, 666-669.
53. Graham, F. L.; Smiley, J.; Russell, W. C.; Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 52, 59-72.
54. Ruetz, S.; Lindsey, A. E.; Ward, C. L.; Kopito, R. R. Functional activation of plasma membrane anion exchangers occurs in a preGolgi compartment. J. Cell Biol. 1993, 121, 37-48.
55. Sterling, D.; Casey, J. R. Transport activity of AE3 chloride/ bicarbonate anion-exchange proteins and their regulation by intracellular pH. Biochem. J. 1999, 344 (Pt 1), 221-229.
56. Casey, J. R.; Ding, Y.; Kopito, R. R. The role of cysteine residues in the erythrocyte plasma membrane anion exchange protein AE1. J. Biol. Chem. 1995, 270, 8521-8527.
57. Cousin, J. L.; Motais, R.; Sola F. Transmembrane exchange of chloride with bicarbonate ion in mammalian red blood cells: Evidence for a sulphonamide-sensitive "carrier". J. Physiol. 1975, 253, 385-399.
58. Sterling, D.; Reithmeier, R. A.; Casey, J. R. A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J. Biol. Chem. 2001, 276, 47886-47894.
59. (a) Sterling, D.; Casey, J. R. Bicarbonate transport proteins. Biochem. Cell Biol. 2002, 80, 483-497.
60. + exchanger binds carbonic anhydrase IV. J. Biol. Chem. 2002, 277, 25239-46.
61. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.